Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference
Rhea-AI Summary
Ultragenyx (NASDAQ: RARE) will participate in Bank of America’s 2026 Healthcare Conference. Company executives Howard Horn, CFO and EVP, and Joshua Higa, Chief of Staff and VP Investor Relations, will appear in a fireside on May 12, 2026 at 2:20 PM PT.
A live and archived webcast will be available on the company’s investor site at https://ir.ultragenyx.com/events-presentations.
Positive
- None.
Negative
- None.
News Market Reaction – RARE
In the May 7 session, RARE gained 0.77%, reflecting a mild positive market reaction. Argus tracked a peak move of +13.3% during that session. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 29 | Earnings call scheduling | Neutral | -1.4% | Announced date and time for Q1 2026 results conference call. |
| Apr 24 | Inducement equity grant | Neutral | -0.5% | Reported RSU inducement awards to new non-executive officers under Nasdaq rules. |
| Apr 2 | BLA resubmission accepted | Positive | +4.8% | FDA acceptance of UX111 BLA resubmission with Priority Review and long-term data. |
| Mar 30 | IND clearance | Positive | -0.4% | FDA cleared IND for UX016 with a planned Phase 1/2 study starting in 2H 2026. |
| Mar 27 | Class action notice | Negative | -0.4% | Notice of application deadline for a class action lawsuit against the company. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Regulatory milestones drew a notably positive move once, but another positive clinical update saw a mild decline, while legal and routine corporate items have been associated with small negative reactions.
Recent news for Ultragenyx spans operational, clinical, and legal updates. On Apr 29, the company scheduled a Q1 2026 results call. An inducement RSU grant was reported on Apr 24. On Apr 2, the FDA accepted the resubmitted BLA for UX111 with a defined PDUFA date and long-term data, and on Mar 30 the FDA cleared the IND for UX016. A class action application deadline notice appeared on Mar 27. These events frame the backdrop for the non-fundamental conference appearance announced today.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and Joshua Higa, Chief of Staff and Vice President of investor relations, will participate in a fireside at Bank of America’s 2026 Healthcare Conference on Tuesday, May 12, 2026, at 2:20 PM PT.
The live and archived webcast of the panel will be accessible from the company’s website at https://ir.ultragenyx.com/events-presentations.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contacts Ultragenyx Pharmaceutical, Inc.
Investors
Joshua Higa
ir@ultragenyx.com
